Incidence and evolution of oxaliplatin-induced eripheral sensory neuropathy in diabetic patients with colorectal cancer: A pooled analysis of three phase III studies

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 754-758

  Ramanathan, R K ^a   Rothenberg, M L ^b   de Gramont, A ^c   Tournigand, C ^c   Goldberg, R M ^d   Gupta, S ^e   Andre T ^f  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e International Clinical Development Oncology   (United States)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Colon cancer; Diabetes mellitus; Folfox; Neuropathy; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT THERAPY; ARTICLE; CANCER GRADING; CANCER STAGING; COLORECTAL CANCER; CONTINUOUS INFUSION; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INCIDENCE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROBABILITY; SENSORY NEUROPATHY;

EID: 77952189860     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp509     Document Type: Article

References (27)

1. Weitz J, Koch M, Debus J et al. Colorectal cancer. Lancet 2005; 365: 153-165.
2. Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 2007; 3: 281-294.
3. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
4. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
5. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
6. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
7. Goldberg RM. N9741:a phase III study comparingirinotecan tooxaliplatin-containing regimens in advanced colorectal cancer. Clin Colorectal Cancer 2002; 2: 81.
8. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29 (Suppl 15): 11-20.
9. Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2003; 2: 597-607.
10. Gamelin L, Capitain O, Morel A et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007; 13: 6359-6368.
11. Lecomte T, Landi B, Beaune P et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12: 3050-3056.
12. Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 2006; 13: 2901-2907.
13. Park SB, Goldstein D, Lin CS et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009; 27: 1243-1249.
14. Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician 2005; 71: 2123-2128.
15. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003; 63: 1549-1563.
16. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46 (Suppl 2): S31-S37.
17. van Dam PS. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2002; 18: 176-184.
18. Vinik AI. Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999; 107 (Suppl 2B): 17S-26S.
19. Cassidy J, Bjarnason GA, Hickish T et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 2006; 24 (Suppl): 18S (Abstr 3507).
20. Gamelin L, Boisdron-Celle M, Morel A et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26: 1188-1189.
21. Hochster H, Grothey A, Shpilsky A, Childs B. Effect of intravenous calcium and magnesium versus placebo on response to FOLFOX+bevacizumab in the CONcePT trial. In 2008 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008 (Abstr 280).
22. Nikcevich DA, Grothey A, Sloan JA et al. Effect of intravenous calcium and magnesium on oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol 2008; 26 (Suppl): 15S (Abstr 4009).
23. de Gramont A, Buyse M, Abrahantes JC et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 3224-3229.
24. Maindrault-Goebel F, Tournigand C, Andre T et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15: 1210-1214.
25. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24: 394-400.
26. Blonde L. State of diabetes care in the United States. Am J Manag Care 2007; 13 (Suppl 2): S36-S40.
27. Sloan FA, Bethel MA, Ruiz D Jr et al. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008; 168: 192-199.